Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bone disease in multiple myeloma.

Øyvind Hjertner1, Therese Standal, Magne Børset

  • 1Department of Haematology, St. Olav University Hospital, Institute of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology N-7006 Trondheim, Norway. Oyvind.hjertner@ntnu.no

Medical Oncology (Northwood, London, England)
|February 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune-cold NSCLC tumors harbor tumor-associated macrophages with elevated expression of immunoglobulin genes.

Cancer immunology, immunotherapy : CII·2026
Same author

TCR T cells targeting IgA- and IgG-expressing multiple myeloma.

Blood·2026
Same author

Multiplexed Imaging Reveals Immune-Metabolic Niches in Multiple Myeloma Linked to Progression and Bone Disease.

Blood cancer discovery·2026
Same author

Mechanical Manipulation of Fat: From Lipoaspirate to SVF Concentrate.

Plastic and reconstructive surgery·2025
Same author

Adaptive designs in randomized clinical trials: reanalysis of the HOVON87/NMSG18 multiple myeloma trial.

EClinicalMedicine·2025
Same author

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform.

HemaSphere·2025
Same journal

Nanomedicine-based sensitization and resistance reversal in immunotherapy of clear cell renal cell carcinoma: from tumor microenvironment to precision delivery.

Medical oncology (Northwood, London, England)·2026
Same journal

Expedited regulatory approval pathways for novel oncology drugs.

Medical oncology (Northwood, London, England)·2026
Same journal

Disulfidptosis and its molecular mechanisms in cancer: mechanisms, regulation, and therapeutic potential.

Medical oncology (Northwood, London, England)·2026
Same journal

DC-intrinsic SHP1 restrains central memory CD8⁺ T cell formation via the TCF-1/Wnt/β-Catenin axis.

Medical oncology (Northwood, London, England)·2026
Same journal

Site-specific trastuzumab Fab-DM1 via butelase-1 with ABD fusion for potent HER2-positive tumor control.

Medical oncology (Northwood, London, England)·2026
Same journal

Unraveling the link between genomic instability and tumor immune evasion in oral squamous cell carcinoma: Role of CBMN assay and emerging perspectives.

Medical oncology (Northwood, London, England)·2026
See all related articles

Multiple myeloma disrupts bone remodeling by altering the RANK signaling system, leading to osteolytic lesions. New therapies targeting bone homeostasis offer promising treatment avenues.

Area of Science:

  • Bone biology
  • Oncology
  • Pharmacology

Background:

  • The discovery of the RANK signaling system (receptor activator of nuclear factor-kappaB, receptor activator of nuclear factor-kappaB ligand, and osteoprotegerin) revolutionized understanding of bone resorption.
  • Dysregulation of this system is implicated in multiple myeloma, initially compensated by osteoblast activity but ultimately leading to osteolytic lesions.

Purpose of the Study:

  • To review factors influencing osteoclast and osteoblast function in the context of multiple myeloma.
  • To discuss potential therapeutic targets for bone homeostasis in multiple myeloma beyond current bisphosphonate treatment.

Main Methods:

  • Literature review of factors affecting bone remodeling.
  • Analysis of the RANK signaling pathway's role in multiple myeloma pathogenesis.

Related Experiment Videos

  • Discussion of therapeutic targets for bone homeostasis.

    • Main Results:

    • The RANK signaling system is key to bone resorption and is abnormally regulated in multiple myeloma.
    • Factors such as hepatocyte growth factor, macrophage inflammatory protein-1alpha, bone morphogenetic proteins, and the Wnt system also play roles.
    • Current treatment primarily uses bisphosphonates, but the complex regulation offers numerous other therapeutic targets.

    Conclusions:

    • Understanding the complex regulation of bone homeostasis in multiple myeloma reveals multiple targets for novel therapeutic strategies.
    • Targeting these pathways could lead to improved management of osteolytic lesions in multiple myeloma patients.